Medicover Genetics LtdSA.F59Medicover Genetics is a leading innovator in genetic diagnostics, laboratory enablement, and clinical testing, with over 25 years of experience supporting healthcare systems worldwide. The company offers a comprehensive portfolio of genetic testing services and clinical counselling, supported by certified diagnostic products and platforms.
At the core of its offering is the proprietary Technology Transfer Platform—an end-to-end genomics solution that enables partner laboratories worldwide to perform high-precision genetic tests in-house.
Medicover Genetics’ CE-marked, IVDR-certified portfolio, developed through decades of clinical and medical expertise, includes VERACITY™, a non-invasive prenatal test (NIPT), and TarCET™, a suite of clinical assays addressing hereditary cancers, cardiovascular and metabolic disorders, infertility, neonatal conditions, and other critical health areas.
Driven by continuous research and development, Medicover Genetics is actively expanding into advanced areas such as liquid biopsy for therapy selection and minimal residual disease (MRD) testing. Its laboratories are CAP and ISO 15189 accredited, ISO 9001, and ISO 13485 certified, and comply with GMP and GCP, ensuring the highest quality standards.
With a presence across Europe, Asia, and Africa, Medicover Genetics collaborates closely with laboratories and clinicians to deliver scalable, high-impact genetic solutions that support personalized medicine and enable informed clinical decision-making. www.medicover-genetics.com
Medicover Genetics is part of Medicover, a leading international healthcare and diagnostic services company founded in 1995 and listed on Nasdaq Stockholm. www.medicover.com
